 Heres a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks Biotech Stocks Hitting 52-week highs on Feb. 12 AbbVie Inc NYSE: ABBV Agile Therapeutics Inc NASDAQ: AGRX Akebia Therapeutics Inc NASDAQ: AKBA Allergan plc NYSE: AGN Alnylam Pharmaceuticals, Inc. NASDAQ: ALNY Anavex Life Sciences Corp NASDAQ: AVXL Aptose Biosciences Inc NASDAQ: APTO AtriCure Inc. NASDAQ: ATRC AVITA MED LTDS ADR NASDAQ: RCEL Avrobio Inc NASDAQ: AVRO Beam Therapeutics Inc NASDAQ: BEAM Brainstorm Cell Therapeutics Inc NASDAQ: BCLI ChemoCentryx Inc NASDAQ: CCXI Cytokinetics, Inc. NASDAQ: CYTK DexCom, Inc. NASDAQ: DXCM Esperion Therapeutics Inc NASDAQ: ESPR Fate Therapeutics Inc NASDAQ: FATE ITAMAR MED LTDS ADR NASDAQ: ITMR Masimo Corporation NASDAQ: MASI Medpace Holdings Inc NASDAQ: MEDP NeoGenomics, Inc. NASDAQ: NEO Novartis AG NYSE: NVS Ocular Therapeutix Inc NASDAQ: OCUL PAVmed Inc NASDAQ: PAVM Penumbra Inc NYSE: PEN Prevail Therapeutics Inc NASDAQ: PRVL reacted to the FDA according Orphan Drug Designation to its experimental gene therapy PR001 for treating Gaucher disease PTC Therapeutics, Inc NASDAQ: PTCT Repligen Corporation NASDAQ: RGEN Tandem Diabetes Care Inc NASDAQ: TNDM West Pharmaceutical Services Inc. 